Skip to main content
IMDX
NASDAQ Life Sciences

iMDx的GraftAssure检测获得新临床数据和FDA提交细节的推动

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$2.92
Mkt Cap
$96.504M
52W Low
$2.33
52W High
$8.51
Market data snapshot near publication time

summarizeSummary

Insight Molecular Diagnostics宣布，将在三个主要国际会议上展示支持其旗舰GraftAssure检测的新独立临床数据。该公司还提供了关于GraftAssureDx（其用于临床的版本）的FDA提交的具体细节，该提交于2026年3月25日通过Class II de novo途径提交。这一消息建立在公司最近的10-K文件中提到的“关键FDA提交”之上，提供了至关重要的具体细节和新的临床验证。对于一个市值约为9600万美元的生命科学公司，独立的积极数据和产品针对20亿美元可-address市场的详细监管进展都非常重要，表明商业化取得了重大进展。投资者将关注这些展示的结果和FDA的审查过程。

在该公告发布时，IMDX的交易价格为$2.92，交易所为NASDAQ，所属行业为Life Sciences，市值约为$9650.4万。 52周交易区间为$2.33至$8.51。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed IMDX - Latest Insights

IMDX
Apr 27, 2026, 7:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Broadwood Partners Increases Stake to 39.7%, Signals Intent for Shareholder Value Creation
Sentiment: Positive
View Wiseek Article
IMDX
Apr 27, 2026, 7:08 PM EDT
Filing Type: 4
Importance Score:
9
Broadwood Partners, a 10% owner, significantly increases stake in Insight Molecular Diagnostics with over $2M in new purchases
Sentiment: Positive
View Wiseek Article
IMDX
Apr 20, 2026, 7:24 PM EDT
Filing Type: 4
Importance Score:
8
10% Owner Broadwood Partners Increases Stake with $652K Open Market Purchase
Sentiment: Positive
View Wiseek Article
IMDX
Apr 14, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
iMDx's GraftAssure Assay Gains Momentum with New Clinical Data, FDA Submission Details
Sentiment: Positive
View Wiseek Article
IMDX
Mar 26, 2026, 4:13 PM EDT
Filing Type: 10-K
Importance Score:
8
Insight Molecular Diagnostics Resolves Going Concern, Secures $24.6M in New Capital, and Submits Key Product to FDA
Sentiment: Positive
View Wiseek Article
IMDX
Mar 26, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Insight Molecular Diagnostics Submits Key Transplant Diagnostic for FDA Review, Reports Q4 Results
Sentiment: Positive
View Wiseek Article
IMDX
Mar 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Second Study Affirms iMDx GraftAssure Superiority, Enabling First-Ever Transplant Rejection 'Rule-In' Option
Sentiment: Positive
View Wiseek Article
IMDX
Mar 03, 2026, 8:07 AM EST
Source: Reuters
Importance Score:
8
Graftassuredx Advances Toward FDA Submission as Insight Molecular Diagnostics Completes Key Milestones
Sentiment: Positive
View Wiseek Article
IMDX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Insight Molecular Diagnostics Partners with Quest Diagnostics for GraftAssureCore™ Test Collection
Sentiment: Positive
View Wiseek Article
IMDX
Feb 12, 2026, 7:52 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Activist Investor Broadwood Partners Increases Stake to 37.4% with $3M Premium Purchase
Sentiment: Positive
View Wiseek Article